Christopher T. Giordano
2021
In 2021, Christopher T. Giordano earned a total compensation of $860.9K as President and Chief Executive Officer at Tenax Therapeutics.
Compensation breakdown
Non-Equity Incentive Plan | $85,938 |
---|---|
Option Awards | $581,471 |
Salary | $183,413 |
Other | $10,091 |
Total | $860,913 |
Giordano received $581.5K in option awards, accounting for 68% of the total pay in 2021.
Giordano also received $85.9K in non-equity incentive plan, $183.4K in salary and $10.1K in other compensation.
Rankings
In 2021, Christopher T. Giordano's compensation ranked 9,260th out of 12,415 executives tracked by ExecPay. In other words, Giordano earned more than 25.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 9,260 out of 12,415 | 25th |
Division Manufacturing | 4,104 out of 5,508 | 26th |
Major group Chemicals And Allied Products | 1,809 out of 2,378 | 24th |
Industry group Drugs | 1,608 out of 2,099 | 23rd |
Industry Pharmaceutical Preparations | 1,193 out of 1,549 | 23rd |
Source: SEC filing on April 28, 2022.
Giordano's colleagues
We found four more compensation records of executives who worked with Christopher T. Giordano at Tenax Therapeutics in 2021.